Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667719 · ClinicalTrials.gov registry record · Phase 3
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
A Phase 3 study of Essential Hypertension, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 564
- Enrollment target
- 8
- Study locations
NCT00667719: Completed Phase 3 study of Essential Hypertension, sponsored by Novartis.
NCT00667719 is a Phase 3 study of Essential Hypertension that has completed, run by Novartis. The registered enrollment target is 564 participants, below the 733-participant average among 8 other Essential Hypertension trials with a reported enrollment target (23% lower). The trial reports 8 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00667719, a Phase 3 study of Essential Hypertension, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 564 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study tested the safety of the combination of aliskiren/amlodipine/hydrochlorothiazide in participants with essential hypertension.
Primary Outcome
An AE was defined as the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug, even if the event is not considered to be related to study drug. An SAE was defined as an event which was fatal or life-threatening, resulted in persistent or significant disability/incapacity, constituted a congenital anomaly/birth defect, required inpatient hospitalization or prolongation of existing hospitalization, was medically significant, i.e. de
Conditions Studied
Interventions
- DRUG Amlodipine
- DRUG Aliskiren
- DRUG Hydrochlorothiazide
Study Locations (8)
Other
- Investigative Site - Belgium
- Investigative Site - Egypt
- Investigative Site - Germany
- Investigative Site - Poland
- Investigative Site - Slovakia
- Investigative Site - Spain
- Investigative Site - Turkey
Texas
- Investigative Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2008-06-05 |
| Est. Completion | 2009-10-05 |
| Phase | Phase 3 |
What the finished NCT00667719 record still lists
NCT00667719 is an interventional study that assigns participants to a tested intervention. The registered 564 participants enrollment target is mid-sized for trials with a published cap, below the 733-participant average among 8 other Essential Hypertension trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Essential Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Amlodipine is the first listed.
NCT00667719 lists 8 locations in 2 states (Other, Texas).
Frequently Asked Questions
What is clinical trial NCT00667719 about?
NCT00667719 is a clinical study titled "A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension". This study tested the safety of the combination of aliskiren/amlodipine/hydrochlorothiazide in participants with essential hypertension.
What is the current status of trial NCT00667719?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 564 participants. The study started on 2008-06-05. Estimated completion is 2009-10-05.
What conditions does trial NCT00667719 study?
This clinical trial studies the following conditions: Essential Hypertension.
What interventions are being tested in trial NCT00667719?
The interventions under investigation include: Amlodipine (DRUG), Aliskiren (DRUG), Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00667719?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00667719 being conducted?
This trial has 8 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Essential Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00667719's enrollment target sits among peer trials
564 5th of 8 higher than 4 of 8 other Essential Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Essential Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
COMPLETED · Phase 3
-
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension
COMPLETED · Phase 3
-
Childhood-Onset Essential Hypertension Natural History Study
RECRUITING
-
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
ACTIVE NOT RECRUITING
-
Uric Acid in Essential Hypertension in Children
COMPLETED · Phase 2
-
Hypertension: Prediction of Biofeedback Success
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06188520 · 564 participants · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
- NCT07125326 · 564 participants · NA
How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI